Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$35.75 USD
-0.41 (-1.13%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $35.74 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COLL 35.75 -0.41(-1.13%)
Will COLL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?
Other News for COLL
Is COLL ready to move higher? 50 Day Moving Average Support shows up after climbing 1.74%
Lower Bollinger Band Walk appears for COLL after 0.22% move
Is COLL poised for gains? Crossed Above 50 Day Moving Average shows up after advancing 2.0%
COLL Fell Below 50 Day Moving Average on September 15
COLL Fell Below 20 Day Moving Average on September 12